A 28-year-old male at ~20% body fat is generally better off avoiding trenbolone and even relying on oral Anavar (oxandrolone) for fat loss, because neither addresses the root drivers of fat gain and both carry disproportionate risk for the goal. Trenbolone is extremely potent and tends to amplify cardiovascular strain (lipids, blood pressure), insulin resistance, sleep disruption, and mood issues—problems that are often already present or more likely at higher body fat levels—while not being necessary for losing fat. Anavar is milder but still suppressive and can negatively affect cholesterol, and fat loss from it is indirect at best. In contrast, a conservative foundation like testosterone cypionate ~200 mg/week (if medically appropriate) provides stable androgen levels that support muscle retention, recovery, and overall function without the extreme side effects, while a GLP-1/GIP agent like tirzepatide directly targets appetite control, caloric intake, and insulin sensitivity—the primary levers for fat loss. Combined with diet and training, this approach is more aligned with the physiology of fat reduction and is typically more sustainable and manageable than using high-risk compounds that don’t directly drive fat loss.